Mr Jeffrey Osterman > Weil, Gotshal & Manges LLP > New York, United States > Lawyer Profile

Weil, Gotshal & Manges LLP handles licensing issues in regard to M&A, private equity, banking & finance and restructuring matters. The firm advises a number of global clients on licensing arrangements, patent acquisitions and other agreements and collaborations. Michael Epstein has more than extensive experience advising technology companies and industry investors on transactions. Charan Sandhu leads the team, with a practice focused on a variety of transactions, such as private equity and M&A, including licensing agreements, while co-head Jeffrey Osterman is vastly experienced in technology-related aspects of transactions. All listed attorneys are based in New York.

Weil, Gotshal & Manges LLP has extremely good experience representing companies and investors operating in the technology and life sciences industries. The team has developed good credentials for standalone technology and IP deals, including advice on patent acquisitions and divestitures, licensing arrangements, research and development collaborations, and technology and IP-focused joint ventures and strategic alliances. A recent highlight included advising Eli Lilly and Company on a license agreement to acquire exclusive global rights to antibody-drug conjugates for the targeted treatment of cancer  from ImmunoGen. This expertise feeds through into the broader support the team provides to the corporate finance group, including advice on corporate M&A and private equity buyouts, banking and finance transactions, and restructuring matters. Jeffrey Osterman  and Charan Sandhu  jointly lead the market-leading team, which also includes Karen Ballack  in Silicon Valley, and the department’s founder and former head, Michael Epstein. All partners are based in New York unless otherwise stated.

Working across offices in New York and California, the team at Weil, Gotshal & Manges LLP has a ‘wide and deep knowledge’ of life sciences related antitrust, IP, and M&A matters. The team often advises biotech, medical devices, and pharmaceutical companies on licensing agreements, commercial litigations, and false advertising issues. Edward Reines co-heads the practice from Silicon Valley, contributing his broad knowledge of willful patent infringement and contentious IP issues, while New York-based co-head Elizabeth Weiswasser is known for her focus on life science patent litigation, often appearing before the PRAB and ITC for pharmaceutical companies. Jeffrey Osterman and Charan Sandhu jointly lead the technology and IP transactions practice from New York, leveraging their expertise in joint developing agreements, strategic alliances, and technology transfer agreements. Based in Silicon Valley, Derek Walter is noted for his life sciences IP litigation capabilities.